Phase 1 study evaluating the safety, distribution, metabolism, and radiation dosimetry of Ultratrace iobenguane I 131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Iobenguane (Primary)
Indications Carcinoid tumour; Neuroendocrine carcinoma; Paraganglioma; Phaeochromocytoma
Focus Pharmacokinetics
Sponsors Molecular Insight Pharmaceuticals

18 Mar 2019 Results of a pooled analysis from NCT00339131; NCT00458952; NCT00874614; NCT00659984 trials presented at the 101st Annual Meeting of the Endocrine Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com